Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors

@article{Stedman2000ReviewAC,
  title={Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors},
  author={C. Stedman and M. Barclay},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2000},
  volume={14}
}
Proton pump inhibitors have dramatically influenced the management of acid‐peptic disorders in recent years. They all have a broadly similar mechanism of action and are extensively metabolized in the liver via cytochromes P450 2C19 and 3A4. There is some variation in their potential for drug interactions due to differences in enzyme inhibition. Relatively few serious adverse effects have been reported for the proton pump inhibitors. 
Proton pump inhibitors
TLDR
A brief review presents the pharmacodynamics and pharmacokinetics of PPIs and presents clincal applications of the drugs in acid-related diseases. Expand
Systematic review: the effects of long‐term proton pump inhibitor use on serum gastrin levels and gastric histology
TLDR
Concerns have been raised about a potential relationship between PPI‐induced hypergastrinaemia and the development of enterochromaffin‐like (ECL) cell hyperplasia, neuroendocrine tumours and gastric cancer during long-term therapy during long‐term therapy. Expand
Pharmacologic Properties of Proton Pump Inhibitors
TLDR
Although they share a common core structure and mechanism of action, it is important to understand the general pharmacology of these agents and how they differ from histamine2‐receptor antagonists in order to optimize PPI therapy. Expand
Review article: the opportunities and benefits of extended acid suppression
TLDR
Despite their clinical efficacy, currently available proton pump inhibitors may not adequately control intragastric acidity during the night in a significant proportion of both healthy subjects and GERD patients, in whom symptom relief remains suboptimal. Expand
The Use of Proton Pump Inhibitors in Children
TLDR
A comprehensive review of the literature on the clinical pharmacology and use of PPIs in the pediatric population suggested that PPIs are highly effective for the management of GERD and related disorders, and are a critical component of triple therapy to eradicate H. pylori. Expand
The Clinical Importance of Proton Pump Inhibitor Pharmacokinetics
TLDR
Lower propensity for double dosing with pantoprazole may also result in lower medication acquisition costs and a reduction in physician visits due to ineffective therapy with the standard dosing of these other agents. Expand
Proton-pump inhibitors : review
TLDR
This review focuses on the use of oral PPIs in the ambulatory setting, and recent concerns regarding the adverse effects of PPIs. Expand
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
TLDR
The emphasis has been laid on the role of proton pump inhibitors widely used nowadays for the treatment of gastric acid diseases and the medicinal chemistry aspects and mechanism of action of irreversible PPIs and APAs at molecular levels. Expand
Proton Pump Inhibitors
TLDR
Tenatoprazole is a new PPI that has a 5- to 7-fold longer elimination half-life than current PPIs and could be potentially more useful for the treatment of gastro-esophageal reflux disease and nocturnal acid breakthrough than other PPIs. Expand
Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy
TLDR
This data indicates that once‐daily dosing of proton pump inhibitors is a viable treatment option for acid‐related disorders and their use in clinical practice is likely to be safe and effective. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 133 REFERENCES
Personal review: is profound acid inhibition safe?
  • Waldum, Brenna
  • Medicine
  • Alimentary pharmacology & therapeutics
  • 2000
Inhibitors of gastric acid secretion, particular proton pump inhibitors, are effective drugs in the treatment and prophylaxis of acid‐related diseases. Proton pump inhibitors are therefore prescribedExpand
The continuing development of proton pump inhibitors with particular reference to pantoprazole
Inhibition of the gastric proton pump is gaining acceptance as the treatment of choice for severe gastrooesophageal reflux disease, and for treatment of duodenal and gastric ulceration. Three ofExpand
Drug Interactions with Proton Pump Inhibitors
TLDR
A synergy has been confirmed between omeprazole and amoxicillin or clarithromycin in the antibacterial effect against Helicobacter pylori and the small proportion of slow metabolisers is at no additional risk for clinically important drug interactions. Expand
Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
Abstract Omeprazole, lansoprazole and pantoprazole are metabolized by several human cytochromes P450, most prominently by CYP2C19 and CYP3A4. Only pantoprazole is also metabolized by aExpand
Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
  • U. Meyer
  • Medicine
  • The Yale journal of biology and medicine
  • 1996
TLDR
Of these drugs, pantoprazole has the lowest potential for interactions, both in vitro and in human volunteer studies. Expand
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection—comparison with omeprazole and lansoprazole
: A recent trend in curative therapy for Helicobacter pylori infection is the so‐called triple therapy, which consists of a proton pump inhibitor (PPI) and two different antimicrobials. VariousExpand
The interaction of proton pump inhibitors with cytochromes P450.
  • G. Tucker
  • Medicine
  • Alimentary pharmacology & therapeutics
  • 1994
An understanding of the role of human cytochromes (CYPs) P450 in the metabolism of proton pump inhibitors (PPIs) is important in assuring the safety of these drugs. Species' differences in theExpand
The continuing development of gastric acid pump inhibitors
TLDR
Inhibition of this pump by clinically useful drugs was achieved by developing derivatives of timoprazole, pyridyl‐2‐methylsulftnyl benzimidazole, two of these derivatives have shown superiority in acid control and therefore in therapy for peptic ulcer disease compared to the available H2‐receptor antagonists. Expand
A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjects
TLDR
A single daily 20 mg dose significantly decreases 24‐h intragastric acidity and there are no data currently available directly comparing the effect of rabeprazole on 24-h acidity with established proton pump inhibitors. Expand
Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors
  • T. Andersson
  • Chemistry, Medicine
  • Clinical pharmacokinetics
  • 1996
TLDR
All 3 acid pump inhibitors have a very limited potential for drug interactions at the CYP level, and are structurally very similar, even though omeprazole has been more thoroughly studied with regard to different effects. Expand
...
1
2
3
4
5
...